Novel or expanding current targets in fibrinolysis

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Biochemistry

Background:

• Cardiovascular diseases are a leading cause of death and disability globally, imposing a substantial economic burden.
• Current antithrombotic therapies primarily target coagulation and platelet function.
• Existing fibrinolysis-enhancing agents (recombinant plasminogen activators) have limitations including low efficacy, severe side effects, and lack of prophylactic use.

Purpose of the Study:

• To review recent advancements in targeting antifibrinolytic proteins.
• To highlight novel therapeutic strategies for enhancing fibrinolysis.
• To address limitations of current fibrinolytic therapies.

Main Methods:

• Literature review of recent research on antifibrinolytic proteins.
• Analysis of novel therapeutic targets and approaches.
• Synthesis of information on plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor.

Main Results:

• Identification of plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor as key targets.
• Exploration of novel therapeutic avenues beyond recombinant plasminogen activators.
• Discussion of potential for improved efficacy and safety in fibrinolysis enhancement.

Conclusions:

• Targeting antifibrinolytic proteins offers promising new strategies for enhancing fibrinolysis.
• Novel approaches may overcome the limitations of current fibrinolytic therapies.
• Further research into these targets could lead to improved treatments for thrombotic disorders.